Liz interviewed by Michael Garfield ahead of the upcoming BDYHAX conference

In this short interview Liz sums up BioViva’s mission: to transfer gene therapy from the lab to the clinic, and make it affordable for all, starting with small scale production of drugs for the early adopters.  In the next five years BioViva’s goal is to manufacture drugs on a larger scale to bring down prices, as well as to expand its range of therapies on offer to cover all or most of the aspects of the age-damaged cell.  See the full interview on the BDYHAX Youtube page and stay tuned for more of Liz at the conference in February 2018 in Austin TX.

Comment

Avi Roy

- PhD student researching Aging, Mitochondria, and Regenerative Medicine - I currently write for The Conversation (http://bit.ly/13WVyUW) and I have written for The Guardian (http://bit.ly/13WVtRh) - Ringleader of the Oxford University Scientific Society - Co-conspirator at the Oxford Transhumanism and Emerging Technologies - Designing exciting events with the British Science Association Oxford - Advisory Board member at Lifeboat Foundation's Life Extension Board, and the Sustainability Board - Also, I am an Ultimate (frisbee) enthusiast - Yes, unfortunately that's me trying to catch the frisbee